Biomerica, Inc. develops and commercializes diagnostic products used in clinical laboratories, physician offices, point-of-care settings, and consumer channels. The company also performs contract manufacturing and certain diagnostic testing services, with manufacturing primarily in the United States and Mexico. Its portfolio includes clinical lab products, OTC diagnostics, and its inFoods® diagnostic-guided therapy platform, which is aimed at gastrointestinal conditions such as IBS. Biomerica sells through distributors and direct channels, and a meaningful portion of revenue comes from international markets. The business is still in a turnaround and commercialization phase, with management focused on expanding distributor relationships and new product adoption while managing liquidity constraints.
−117,7 %
8,1 %
−84,8 %
−16,2 %
1.62
0.93
| % | |
|---|---|
| Clinical laboratory diagnostics | 55% Tests and diagnostic products sold to clinical labs, hospitals, medical research institutions, and distributors. |
| Point-of-care and physician office diagnostics | 15% Products and services used in patient point-of-care settings and physicians' offices, including direct and distributor sales. |
| Over-the-counter diagnostics | 10% Consumer-facing diagnostic products sold through drug stores, e-commerce, and distributors. |
| Contract manufacturing | 10% Manufacturing services performed for third parties, recognized as work is completed or progresses. |
| Diagnostic-guided therapy products | 10% inFoods®-based products designed to guide treatment for IBS and other inflammatory conditions. |
Biomerica sells to a mix of distributors and end users, with clinical laboratories and patient point-of-care testing...
Buy diagnostic products for routine testing and are a primary target because they drive recurring product demand.
Buy rapid diagnostic products and inFoods-related offerings for use in patient-facing settings.
Purchase products for resale across domestic and international markets and are critical to market access.
Buy consumer diagnostic products through drugstores and online channels to reach end users directly.
Purchase specialized diagnostics for clinical use, validation, and research applications.
Buy diagnostic and contract manufacturing services for development, testing, or commercialization support.
Biomerica manufactures primarily in the United States and Mexico, with Biomerica de Mexico operating as a significant...
Biomerica's near-term strategy is centered on expanding commercialization of inFoods® IBS and building broader adoption...
The product is a key growth driver and a proof point for the company's diagnostic-guided therapy platform.
Third-party partners can extend market reach without requiring the company to build a large direct sales footprint.
The company has recurring losses and limited cash, so expense control is necessary to fund operations and commercialization.
Biomerica faces substantial going-concern and financing risk because it has a history of operating losses, negative...
Management states current cash is insufficient to meet operating cash requirements and strategic growth objectives over the next twelve months.
A small number of customers accounted for a large share of quarterly sales and receivables, making results sensitive to order timing or loss of a key account.
Sales in Europe, China, and other countries depend on maintaining certifications and meeting evolving quality and IVDR requirements.
A significant manufacturing facility is located in Mexico, exposing the company to local economic, political, labor, and import/export risks.
inFoods® and other new products must gain physician adoption and distributor support to generate meaningful revenue.
BMRA · In Vitro & In Vivo Diagnostic Substances
BMEA · Pharmaceutical Preparations
BTCY · Surgical & Medical Instruments & Apparatus
PHGE · Biological Products, (No Diagnostic Substances)
IBO · Pharmaceutical Preparations
BICX · Services-Specialty Outpatient Facilities, NEC
: 11/08/2026